Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Armirotti

Showing results (141-150 of 158) with videos related to

Pageof 16
Sort By:
Journal of Medicinal Chemistry|December 8, 2020
Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase InhibitorsSamantha Caputo, Simona Di Martino, Vincenzo Cilibrasi, et al.
Angewandte Chemie (International Ed. in English)|December 16, 2014
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitorsFederica Prati, Angela De Simone, Paola Bisignano, et al.
Acta Neuropathologica|March 14, 2016
Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat dietAnna Rocchi, Carmelo Milioto, Sara Parodi, et al.
Journal of Medicinal Chemistry|March 17, 2020
Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase InhibitorsSimona Di Martino, Piero Tardia, Vincenzo Cilibrasi, et al.
Scientific Reports|July 15, 2017
Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's diseaseAlba Di Pardo, Enrico Amico, Abdul Basit, et al.
Scientific Reports|May 26, 2018
Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's diseaseAlba Di Pardo, Enrico Amico, Abdul Basit, et al.
Brain : a Journal of Neurology|July 29, 2025
Connectomic and behavioural alterations in creatine transporter deficiency are partially normalized by gene therapyCaterina Montani, Ludovica Iovino, Federica Di Vetta, et al.
Angewandte Chemie (International Ed. in English)|July 13, 2016
Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple SclerosisMarco Migliore, Silvia Pontis, Angel Luis Fuentes de Arriba, et al.
Iscience|September 15, 2025
CDC42-effector interaction inhibitors alter patterns of vessel arborization in skin and tumors <i>in vivo</i>Linh M Vuong, Stephanie Hachey, Jessica Shiu, et al.
Molecular Therapy. Nucleic Acids|December 30, 2025
Synergic microRNAs suppress human glioblastoma progression by modulating clinically relevant targetsSilvia Rancati, Rui C Pereira, Michele Schlich, et al.
Pageof 16

Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Journal of Medicinal Chemistry|December 8, 2020
Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase InhibitorsSamantha Caputo, Simona Di Martino, Vincenzo Cilibrasi, et al.
Angewandte Chemie (International Ed. in English)|December 16, 2014
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitorsFederica Prati, Angela De Simone, Paola Bisignano, et al.
Acta Neuropathologica|March 14, 2016
Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat dietAnna Rocchi, Carmelo Milioto, Sara Parodi, et al.
Journal of Medicinal Chemistry|March 17, 2020
Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase InhibitorsSimona Di Martino, Piero Tardia, Vincenzo Cilibrasi, et al.
Scientific Reports|July 15, 2017
Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's diseaseAlba Di Pardo, Enrico Amico, Abdul Basit, et al.
Scientific Reports|May 26, 2018
Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's diseaseAlba Di Pardo, Enrico Amico, Abdul Basit, et al.
Brain : a Journal of Neurology|July 29, 2025
Connectomic and behavioural alterations in creatine transporter deficiency are partially normalized by gene therapyCaterina Montani, Ludovica Iovino, Federica Di Vetta, et al.
Angewandte Chemie (International Ed. in English)|July 13, 2016
Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple SclerosisMarco Migliore, Silvia Pontis, Angel Luis Fuentes de Arriba, et al.
Iscience|September 15, 2025
CDC42-effector interaction inhibitors alter patterns of vessel arborization in skin and tumors <i>in vivo</i>Linh M Vuong, Stephanie Hachey, Jessica Shiu, et al.
Molecular Therapy. Nucleic Acids|December 30, 2025
Synergic microRNAs suppress human glioblastoma progression by modulating clinically relevant targetsSilvia Rancati, Rui C Pereira, Michele Schlich, et al.
Pageof 16